Jason Bednar
Stock Analyst at Piper Sandler
(2.20)
# 2,807
Out of 5,111 analysts
190
Total ratings
40.69%
Success rate
-3.46%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Reiterates: Overweight | $83 → $94 | $81.04 | +15.99% | 15 | Dec 5, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $200 → $190 | $196.39 | -3.25% | 11 | Nov 7, 2025 | |
| ICUI ICU Medical | Maintains: Overweight | $153 → $172 | $147.07 | +16.95% | 3 | Nov 7, 2025 | |
| SOLV Solventum | Maintains: Overweight | $94 → $98 | $80.59 | +21.60% | 8 | Nov 7, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $17 | $16.70 | +1.80% | 3 | Nov 5, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $105 → $109 | $86.85 | +25.50% | 14 | Oct 31, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $190 → $200 | $162.89 | +22.78% | 32 | Oct 30, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $134.52 | +56.11% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $21.90 | -13.24% | 13 | Aug 1, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $2.48 | +0.81% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.93 | +162.95% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $5.77 | -39.34% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.37 | +40.72% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $77.05 | -0.06% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.12 | +44.23% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $253.03 | +4.73% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.36 | +78.57% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.14 | +36.19% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.92 | +2,083.41% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $554.58 | -32.92% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $82.25 | +15.50% | 1 | Apr 19, 2023 |
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $81.04
Upside: +15.99%
Becton, Dickinson and Company
Nov 7, 2025
Maintains: Neutral
Price Target: $200 → $190
Current: $196.39
Upside: -3.25%
ICU Medical
Nov 7, 2025
Maintains: Overweight
Price Target: $153 → $172
Current: $147.07
Upside: +16.95%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94 → $98
Current: $80.59
Upside: +21.60%
Sotera Health Company
Nov 5, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $16.70
Upside: +1.80%
Merit Medical Systems
Oct 31, 2025
Reiterates: Overweight
Price Target: $105 → $109
Current: $86.85
Upside: +25.50%
Align Technology
Oct 30, 2025
Reiterates: Overweight
Price Target: $190 → $200
Current: $162.89
Upside: +22.78%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $134.52
Upside: +56.11%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $21.90
Upside: -13.24%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $2.48
Upside: +0.81%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.93
Upside: +162.95%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $5.77
Upside: -39.34%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.37
Upside: +40.72%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $77.05
Upside: -0.06%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.12
Upside: +44.23%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $253.03
Upside: +4.73%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.36
Upside: +78.57%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $5.14
Upside: +36.19%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.92
Upside: +2,083.41%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $554.58
Upside: -32.92%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $82.25
Upside: +15.50%